- ISIN
- US36870H1032
- CUSIP
- 36870H103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 26, 2023
Highlights
- Market Cap
- $132.45M
- Enterprise Value
- $125.99M
- EPS (TTM)
- -$0.85
- Total Revenue (TTM)
- $8.00K
- Gross Profit (TTM)
- -$283.00K
- EBITDA (TTM)
- -$24.96M
- Year Range
- $2.29 - $8.54
- Target Price
- $17.33
- ROA (TTM)
- -103.73%
- ROE (TTM)
- -146.51%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GNLX Performance Chart
Genelux Corporation (GNLX) is down 31.2% since the beginning of the year. At $3 per share, GNLX is trading 64.9% below its 52-week high of $9.
Loading charts...
Returns By Period
Genelux Corporation (GNLX) has returned -31.19% so far this year and 16.73% over the past 12 months.
Genelux Corporation
- 1D
- 1.69%
- 1M
- 5.26%
- YTD
- -31.19%
- 6M
- -35.48%
- 1Y
- 16.73%
- 3Y*
- -52.56%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
GNLX Monthly Returns History
Based on dividend-adjusted daily data since Jan 26, 2023, GNLX's average daily return is +0.16%, while the average monthly return is +4.09%. At this rate, an investment would double in approximately 1.4 years.
Historically, 48% of months were positive and 52% were negative. The best month was Feb 2023 with a return of +159.6%, while the worst month was Apr 2024 at -51.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.
On a daily basis, GNLX closed higher 47% of trading days. The best single day was Mar 6, 2023 with a return of +60.4%, while the worst single day was May 24, 2024 at -43.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -38.99% | 12.03% | -18.79% | 10.33% | 14.23% | -1.64% | -31.19% | ||||||
| 2025 | 67.37% | 5.82% | -35.41% | -0.37% | -10.04% | 18.60% | 18.12% | -1.77% | 26.13% | 92.38% | -31.19% | -21.58% | 84.75% |
| 2024 | -24.48% | -31.00% | -11.92% | -51.63% | -12.86% | -28.04% | 0.00% | 11.28% | 9.22% | 35.86% | -16.46% | -12.27% | -83.15% |
| 2023 | -6.87% | 159.64% | 86.55% | -12.80% | 12.44% | 20.29% | -35.61% | 14.76% | 1.28% | -40.75% | -17.99% | 17.73% | 127.80% |
Benchmark Metrics
Genelux Corporation has an annualized alpha of 12.24%, beta of 1.45, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since January 27, 2023.
- This stock participated in 179.72% of S&P 500 Index downside but only -0.82% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.24%
- Beta
- 1.45
- R²
- 0.04
- Upside Capture
- -0.82%
- Downside Capture
- 179.72%
Return for Risk
Risk / Return Rank
GNLX ranks 49 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Genelux Corporation (GNLX) and compare them to S&P 500 Index.
| GNLX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.05 | ||
| Sortino ratioReturn per unit of downside risk | -2.19 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.41 | -0.28 |
| Calmar ratioReturn relative to maximum drawdown | 0.23 | 2.93 | -2.70 |
| Martin ratioReturn relative to average drawdown | 0.36 | 13.52 | -13.16 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Genelux Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Genelux Corporation was 95.74%, occurring on Aug 5, 2024. The portfolio has not yet recovered.
The current Genelux Corporation drawdown is 92.11%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -95.74%Aug 2024 | 1y 1mo | — | 2y 11moJun 2023 - now |
2023 bear market2023 | -51.91%Mar 2023 | 6d | 9d | 15dMar 2023 - Mar 2023 |
2023 bear market2023 | -24.63%May 2023 | 1mo 15d | 29d | 2mo 14dMar 2023 - Jun 2023 |
2023 pullback2023 | -9.59%Feb 2023 | 7d | 12d | 19dJan 2023 - Feb 2023 |
2023 pullback2023 | -4.56%Mar 2023 | 0s | 1d | 1dMar 2023 - Mar 2023 |
Drawdown Indicators
| GNLX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.74% | -56.78% | -38.96% |
Max Drawdown (1Y)Largest decline over 1 year | -72.09% | -9.10% | -62.99% |
Max Drawdown (3Y)Largest decline over 3 years | -95.74% | -18.90% | -76.84% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -92.11% | -0.74% | -91.37% |
Average DrawdownAverage peak-to-trough decline | -73.12% | -10.72% | -62.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 46.22% | 1.97% | +44.25% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Genelux Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Genelux Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GNLX relative to other companies in the Biotechnology industry. Currently, GNLX has a P/S ratio of 14,734.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GNLX in comparison with other companies in the Biotechnology industry. Currently, GNLX has a P/B value of 5.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GNLX
Add Genelux Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GNLX